NO20055857L - Materialer og fremgangsmater til immunisering mot FIV-infeksjon - Google Patents

Materialer og fremgangsmater til immunisering mot FIV-infeksjon

Info

Publication number
NO20055857L
NO20055857L NO20055857A NO20055857A NO20055857L NO 20055857 L NO20055857 L NO 20055857L NO 20055857 A NO20055857 A NO 20055857A NO 20055857 A NO20055857 A NO 20055857A NO 20055857 L NO20055857 L NO 20055857L
Authority
NO
Norway
Prior art keywords
methods
fiv
materials
present
compositions
Prior art date
Application number
NO20055857A
Other languages
English (en)
Inventor
Janet K Yamamoto
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of NO20055857L publication Critical patent/NO20055857L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører fremgangsmåter og preparater for å beskytte kattedyr mot infeksjon fra FIV ved å benytte immunogener som er avledet fra primatimmunsviktvirus, inkludert HIV og SIV. Fremgangsmåter for å vaksinere kattedyr med foreliggende vaksinepreparater er beskrevet. Kattedyr som er vaksinert ifølge fremgangsmåtene og preparatene ifølge foreliggende oppfinnelse oppviser beskyttende humoral og cellulær immunrespons overfor FIV når de blir utfordret med FIV.
NO20055857A 2003-05-12 2005-12-09 Materialer og fremgangsmater til immunisering mot FIV-infeksjon NO20055857L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47006603P 2003-05-12 2003-05-12
PCT/US2004/014928 WO2004100985A2 (en) 2003-05-12 2004-05-12 Materials and methods for immunizing against fiv infection

Publications (1)

Publication Number Publication Date
NO20055857L true NO20055857L (no) 2006-02-10

Family

ID=33452358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055857A NO20055857L (no) 2003-05-12 2005-12-09 Materialer og fremgangsmater til immunisering mot FIV-infeksjon

Country Status (14)

Country Link
US (2) US20050031639A1 (no)
EP (1) EP1622644A2 (no)
JP (1) JP2006528244A (no)
KR (1) KR20060032138A (no)
CN (1) CN100387301C (no)
AU (1) AU2004238367A1 (no)
BR (1) BRPI0410422A (no)
CA (1) CA2525641A1 (no)
MX (1) MXPA05012270A (no)
NO (1) NO20055857L (no)
NZ (1) NZ543381A (no)
RU (1) RU2005138501A (no)
WO (1) WO2004100985A2 (no)
ZA (1) ZA200508853B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060032138A (ko) 2003-05-12 2006-04-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 에프아이브이 감염에 대항하여 면역화를 위한 물질 및 방법
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
JP2007505320A (ja) 2003-09-11 2007-03-08 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスの検出のための方法と装置
AU2004304348B2 (en) 2003-12-18 2009-02-26 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
CA2556141A1 (en) 2004-02-19 2005-09-01 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
EP1761564A1 (en) * 2004-06-30 2007-03-14 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
JP4307505B2 (ja) 2004-06-30 2009-08-05 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスの検出のための方法と装置
EP1761556A1 (en) 2004-06-30 2007-03-14 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein
US7291338B2 (en) 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
EP2553452B1 (en) 2010-04-02 2015-03-04 IDEXX Laboratories, Inc. Detection of feline immunodeficiency virus
WO2013040766A1 (zh) * 2011-09-21 2013-03-28 中国疾病预防控制中心性病艾滋病预防控制中心 可诱导针对hiv的广谱免疫应答的方法和疫苗
JP2013116869A (ja) * 2011-12-02 2013-06-13 Vaxxinova Kk 細胞内在ウイルスを主成分とする伝染性ファブリキウス嚢病生ワクチン
CN108367065A (zh) * 2015-09-25 2018-08-03 佛罗里达大学研究基金会股份有限公司 用于人和猫疫苗的hiv、siv和fiv的交叉反应性t细胞表位

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861720A (en) * 1986-07-03 1989-08-29 Regents Of The University Of California Oncornavirus vaccines and feline alpha-type interferon
CA1341439C (en) * 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
US6107077A (en) * 1987-08-26 2000-08-22 Yamamoto; Janet K. Feline lymphoid cell lines capable of producing FIV for FIV diagnostics and vaccines
US5118602A (en) * 1987-08-26 1992-06-02 The Regents Of The University Of California Feline T-lymphotropic lentivirus assay
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5480967A (en) * 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments
EP0527760B1 (en) * 1990-04-03 1995-07-19 Genentech, Inc. Methods and compositions for vaccination against hiv
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5229364A (en) * 1991-03-15 1993-07-20 Francesca Chiodi Polypeptides derived from the human immunodeficiency virus endonuclease protein
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1993001278A1 (en) 1991-07-05 1993-01-21 The Regents Of The University Of California Feline lymphoid cell lines capable of producing fiv
EP0670901A1 (en) 1993-03-11 1995-09-13 Akzo Nobel N.V. Polypeptide fragment capable of inducing neutralising antibodies against feline immuno-deficiency virus
US5864027A (en) 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
IT1276509B1 (it) 1995-03-31 1997-10-31 Istituto Superiore Della Sanit Vaccino per la profilassiimmunitaria dell'infezione da virus della immunodeficienza felina del gatto domestico.
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US6254872B1 (en) * 1995-08-25 2001-07-03 University Of Florida Multi-subtype FIV vaccines
ATE297218T1 (de) 1995-08-25 2005-06-15 Univ Florida Impfstoff gegen mehrere fiv-subtypen
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
WO1999036511A2 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
US6503753B1 (en) * 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
EP1078105B1 (en) * 1998-05-12 2004-11-24 Genecure LLC Replication defective hiv vaccine
JP2002533124A (ja) * 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
EP1074625A3 (en) * 1999-06-14 2002-01-02 Pfizer Products Inc. DNA vaccine against feline immunodeficiency virus
KR100354562B1 (ko) * 1999-12-06 2002-09-30 주식회사 제넥신 원숭이에서 ＳＩＶｍａｃ２３９의 감염에 대한 방어를유도하는 ＡＩＤＳ ＤＮＡ 백신
AU2001271976A1 (en) * 2000-07-07 2002-01-21 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
WO2002067984A2 (en) * 2001-02-22 2002-09-06 University Of Florida Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection
KR20060032138A (ko) 2003-05-12 2006-04-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 에프아이브이 감염에 대항하여 면역화를 위한 물질 및 방법
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection

Also Published As

Publication number Publication date
JP2006528244A (ja) 2006-12-14
US8703145B2 (en) 2014-04-22
CN100387301C (zh) 2008-05-14
CA2525641A1 (en) 2004-11-25
RU2005138501A (ru) 2006-06-27
KR20060032138A (ko) 2006-04-14
WO2004100985A2 (en) 2004-11-25
MXPA05012270A (es) 2006-02-10
US20050031639A1 (en) 2005-02-10
NZ543381A (en) 2008-04-30
AU2004238367A1 (en) 2004-11-25
AU2004238367A2 (en) 2004-11-25
BRPI0410422A (pt) 2006-05-30
EP1622644A2 (en) 2006-02-08
US20100111899A1 (en) 2010-05-06
CN1812810A (zh) 2006-08-02
ZA200508853B (en) 2007-02-28
WO2004100985A3 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
NO20055857L (no) Materialer og fremgangsmater til immunisering mot FIV-infeksjon
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
EP2130921A3 (en) Vaccine for prevention and treatment of hiv-infection
DK1147117T3 (da) Immunologiske adjuvansforbindelser
NO992369D0 (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
DK0848615T3 (da) Muilti-undertyoe-FIV-vacciner
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
DE60336978D1 (de) Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper
FI1855720T4 (fi) Muunnellun rokkoviruksen käyttö immuniteetin nopeaksi indusoimiseksi rokkovirusta tai muita infektoivia aineita vastaan
DE60115051D1 (de) Immunologische adjuvans verbindungen
ATE294857T1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
WO2007079457A3 (en) Materials and methods for immunizing against fiv infection
WO2005027844A3 (en) Dna vaccine compositions and methods of use
WO2008121487A3 (en) Live attenuated virus vaccines for la crosse virus and other bunyaviridae
NO20060395L (no) Antigenholdig dyrevaksine
DK1742656T3 (da) Hidtil ukendt jordnøddeskindekstrakt som adjuvansvaccine
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
WO2004083390A3 (en) Virulent systemic feline calicivirus
RU2006131153A (ru) Способ иммунизации против вирусных инфекций человека и животных с использованием неиммуногенных и слабоиммуногенных вирусных белков и усиления трансмембранного переноса антител внутрь клеток
WO2004062567A3 (en) Arterivirus marker vaccine
CY1113749T1 (el) Συνθεσεις εμβολιων dna και μεθοδοι χρησης τους

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application